ProQR Therapeutics (NASDAQ:PRQR) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01, FiscalAI reports. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%. The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $4.30 million.

ProQR Therapeutics Stock Performance

Shares of PRQR opened at $1.36 on Friday. The company’s fifty day moving average is $1.59 and its 200 day moving average is $1.68. ProQR Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $2.48.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PRQR shares. Chardan Capital reissued a “buy” rating and set a $3.00 target price on shares of ProQR Therapeutics in a research note on Thursday, October 1st. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a report on Thursday, October 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday. HC Wainwright dropped their target price on shares of ProQR Therapeutics to $8.00 and set a “buy” rating for the company in a research report on Thursday, October 1st. Finally, Bank of America started coverage on shares of ProQR Therapeutics in a research report on Thursday, August 20th. They set a “buy” rating and a $8.00 target price for the company. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.60.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company developing RNA-based medicines for genetic diseases. Its research centers on Axiomer, a platform designed to make targeted changes to RNA using the body’s naturally occurring editing machinery. Founded in 2012 and based in Leiden, the Netherlands, ProQR initially focused on RNA therapies for inherited retinal disorders, including Usher syndrome and Leber congenital amaurosis. The company later broadened its emphasis to RNA editing and continues to develop potential treatments for genetic conditions.